Samsung Bioepis Biosimilar Market Report 2nd Edition, Q3 2023 – 7/10/23

SAMSUNG BIOEPIS

Biosimilar Market Report

2nd Edition, Q3 2023

In this second edition of our report, we have included the 8 Humira biosimilars’ WAC price that have launched within pharmacy benefits and updated the most recent market share and ASP trends of all molecules for biosimilar(s) that have launched in the US.

Moving forward each Market Report will consist of comprehensive updates on pricing and market penetration for all marketed biosimilars in the US.

We invite you to download the 2nd Samsung Bioepis Biosimilar Market Report here:

 © 2023 Samsung Bioepis Co., Ltd. All Rights Reserved. 6/2023. [SB_2023_06_29_141_E]